Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase II for Anemia. According to GlobalData, Phase II drugs for Anemia have a 53% phase transition success rate (PTSR) ...

From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...

Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...